Efficacy and Safety of Fucicort® Lipid Cream Compared to Combination Treatment With Fucidin® Cream Followed by Betamethasone (Lianbang Beisong®) Cream and Fucicort® Lipid Cream Vehicle in Clinically Infected Atopic Dermatitis/Eczema
- Conditions
- Interventions
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2019-05-22
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 68
- Registration Number
- NCT03395132
- Locations
- 🇨🇳
The First Hospital of Dalian Medical University, Dalian, Liaoning, China
🇨🇳Beijing Children's Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 380
- Registration Number
- NCT03363854
- Locations
- 🇪🇸
Fundación Hospital Alcorcón, Madrid, Spain
🇪🇸Hospital General de Valencia, Valencia, Spain
🇩🇪St. Josef-Hospital, Ruhr-Universitet, Bochum, Germany
A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 210
- Registration Number
- NCT03331835
- Locations
- 🇩🇪
Charité - Universitätsmedizin Berlin Klinik für Dermatologie, Venerologie und Allergologie Psoriasis Studien Zentrum, Berlin, Germany
🇩🇪Fachklinik Bad Bentheim Klinik für Dermatologie, Bad Bentheim, Germany
🇩🇪Rothhaar Studien GmbH Dermatologisches Studienzentrum, Berlin, Germany
Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.
- First Posted Date
- 2017-10-30
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 13
- Registration Number
- NCT03325296
- Locations
- 🇩🇰
Investigational site, Gentofte, Denmark
Multiple Dose Study With Incremental Dosing to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Doses of LEO 32731 in Healthy Male Japanese Subjects.
- First Posted Date
- 2017-07-27
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 26
- Registration Number
- NCT03231124
- Locations
- 🇬🇧
Investigational Site, London, United Kingdom
A Study of Patient Concerns and Treatment Satisfaction in Patients Being Treated With Finacea Foam for Rosacea
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2020-04-01
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 2200
- Registration Number
- NCT03193372
- Locations
- 🇺🇸
Xcenda, LLC, Palm Harbor, Florida, United States
Skin IaM: An Exploratory Clinical Trial to Evaluate Changes in Skin Appearance, Colour, and/or Texture Following the Induction of a Local Inflammatory Skin Response
- Conditions
- Interventions
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 12
- Registration Number
- NCT03192280
- Locations
- 🇦🇺
Investigational Site, Herston, Australia
Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 794
- Registration Number
- NCT03160885
- Locations
- 🇺🇸
Modern Research Associates, PLLC, Dallas, Texas, United States
🇺🇸USC Department of Dermatology, Los Angeles, California, United States
🇺🇸Paddington Testing Company, Inc., Philadelphia, Pennsylvania, United States
Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 802
- Registration Number
- NCT03131648
- Locations
- 🇺🇸
Dermatology Research Associates, Los Angeles, California, United States
🇺🇸PMG Research of Christie Clinic, Chicago, Illinois, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Open-label, Single Center, Non-randomized, Fixed Sequence Phase 1 Drug-drug Interaction Study With LEO 32731 and Midazolam
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 32
- Registration Number
- NCT03126578
- Locations
- 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany